Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06928779 · ClinicalTrials.gov registry record · Phase 1
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT06928779 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 19 participants.
The verdict
NCT06928779, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study will compare the pharmacokinetics (PK) of dazucorilant (CORT113176) between participants with normal hepatic function and participants with hepatic impairment.
Interventions
- DRUG Dazucorilant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2024-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06928779
The ClinicalTrials.gov registry entry for NCT06928779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dazucorilant is the first listed.
NCT06928779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06928779 about?
NCT06928779 is a clinical study titled "Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant". This study will compare the pharmacokinetics (PK) of dazucorilant (CORT113176) between participants with normal hepatic function and participants with hepatic impairment.
What is the current status of trial NCT06928779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2024-10-08. Estimated completion is 2024-12-09.
What interventions are being tested in trial NCT06928779?
The interventions under investigation include: Dazucorilant (DRUG).
Who is sponsoring clinical trial NCT06928779?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.